Sign in to view content

Visual Impact of Central Subfield Thickness (CST) Fluctuation in Patients With nAMD Treated With Anti-VEGFs in VIEW Trials

Dilsher S. Dhoot, MD

Video
Published 2021

Related

Number of Injections and Time to Dry Analysis of Brolucizumab Versus Aflibercept in Patients With Neovascular AMD: 96-Week Data From HAWK and HARRIER
Carl D. Regillo, MD
Annual Meeting Talks
2020
Interim Results and Key Learnings from an Ongoing Phase 2 Study of Encapsulated Cell Therapy Compared to Aflibercept in Patients With Wet AMD
Szilárd Kiss, MD
Annual Meeting Talks
2016
Treatment Switch From Aflibercept to Ranibizumab Pre-filled Syringe in Canadian nAMD and DME Patients in a Real-World Setting: The PRECISE Study
Ananda Kalevar, MD, FRCS(C), DABO
On Demand Cases, Courses, and Papers
2020

Category: AMD-Neovascular

See more